Cardiomyopathy News and Research

RSS

Cardiomyopathy is a group of diseases with primary, usually diffuse, involvement of the myocardium. The myocardial disease is not secondary to ischaemic, valvular, congenital or pericardial disease.

Scientists discover finely tuned mechanism associated with CHD

Scientists at the Gladstone Institutes have identified a finely tuned mechanism by which fetal heart muscle develops into a healthy and fully formed beating heart-offering new insight into the genetic causes of congenital heart disease and opening the door to one day developing therapies to fight this chronic and potentially fatal disorder.

23 Jan 2012

Risk of sudden cardiac arrest while running a marathon is low in the healthy: Study

There have been reports of a marathoner collapsing suddenly with no pulse. Now a large study finds such calamities are rare and usually due to a pre-existing heart problem. The study also found such incidents are increasing as more runners try to go the distance.

12 Jan 2012

Grief and heart attacks linked: Study

Researchers have found that grief might actually break ones heart. A new study shows that people grieving the death of a close loved one could have a heart attack risk that is 20 times higher than normal.

10 Jan 2012

Alnylam files CTA with the U.K. MHRA to initiate ALN-TTR02 Phase I trial in ATTR

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that it has filed a Clinical Trial Application (CTA) with the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) to initiate a Phase I clinical trial with ALN-TTR02, an RNAi therapeutic targeting transthyretin (TTR) for the treatment of TTR-mediated amyloidosis.

7 Jan 2012

Isis announces results from ISIS-TTRRx Phase 1 study on TTR amyloidosis

Isis Pharmaceuticals, Inc. announced today results from a Phase 1 study with ISIS-TTRRx. The results demonstrated that treatment with ISIS-TTRRx produced dose-dependent statistically significant reductions of greater than 80 percent in transthyretin (TTR) protein.

6 Jan 2012

Home-monitoring interventions may benefit patients with heart failure

Heart failure affects 5.8 million people in the U.S. alone and is responsible for nearly 1 million hospitalizations each year, most resulting from a build-up of body fluid in the lungs and other organs due to the heart's inability to pump effectively. The disease needs to be closely tracked in order to avoid such hospitalizations, and home-monitoring interventions may be especially useful, UCLA researchers say.

4 Jan 2012

Researchers identify candidate genes for histiocytoid cardiomyopathy

Researchers are closing in on a rare genetic disorder causing a heart condition in infants. Histiocytoid cardiomyopathy (HC) often causes sudden death before a child reaches 2 years of age. Gene analysis is helping to narrow the many theories surrounding the genetic basis of HC.

4 Jan 2012

FDA nod for pediatric Berlin heart

The U.S. Food and Drug Administration (FDA) has approved the Berlin Heart for pediatric patients waiting for heart transplants. The ventricular assist device is similar to the one worn by former Vice President Dick Cheney but scaled down in size for children and babies.

19 Dec 2011

Study investigates 'missing link' between environmental factors and heart failure

A University of Cambridge study, which set out to investigate DNA methylation in the human heart and the 'missing link' between our lifestyle and our health, has now mapped the link in detail across the entire human genome.

30 Nov 2011

Positive preliminary results from Alnylam's ALN-TTR01 Phase I clinical trial for TTR-mediated amyloidosis

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today positive preliminary results from its Phase I clinical trial with ALN-TTR01, an RNAi therapeutic targeting transthyretin (TTR) for the treatment of TTR-mediated amyloidosis (ATTR).

21 Nov 2011

Stem cell therapy for heart failure: two studies two successes

The Center for Disease Control and Prevention says that heart failure affects nearly 6 million Americans leading to considerable risk of death, diminished quality of like and recurrent hospitalizations. Heart failure occurs when the heart can no longer pump enough blood to the rest of the body. The most common cause of heart failure is coronary artery disease, which narrows the small blood vessels that supply blood and oxygen to the heart.

17 Nov 2011

Women much more likely to suffer from “broken heart syndrome”

Researchers have found that a woman’s heart is broken more easily than a man’s. In fact females are seven to nine times more likely to suffer “broken heart syndrome,” when sudden or prolonged stress like an emotional breakup or death causes overwhelming heart failure or heart attack-like symptoms, the first nationwide study of this finds. Usually patients recover with no lasting damage add researchers.

17 Nov 2011

Alnylam announces new data from ALN-TTR01 Phase I trial on TTR-mediated amyloidosis

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that it will present new data from its ALN-TTR program at the VIIIth International Symposium on Familial Amyloidotic Polyneuropathy being held in Kumamoto, Japan from November 20-22, 2011.

15 Nov 2011

Fetal stem cells play an important role in inducing maternal cardiac repair

Researchers from Mount Sinai School of Medicine have discovered the therapeutic benefit of fetal stem cells in helping the maternal heart recover after heart attack or other injury.

14 Nov 2011

Therapeutic hypothermia recommended for patients with preexisting cardiomyopathy

Cardiomyopathy is common among cardiac arrest survivors. The survival and neuroprotective benefits of therapeutic hypothermia is similar in patients with preexisting cardiomyopathy, compared with those patients without cardiomyopathy, according to a scientific poster being presented Nov. 14 at the American Heart Association (AHA) scientific sessions.

14 Nov 2011

Data shows cost-effectiveness of ZOLL LifeVest Wearable Defibrillator

ZOLL Medical Corporation, a manufacturer of medical devices and related software solutions, announced today that data showing the cost-effectiveness of the LifeVest Wearable Defibrillator was presented in two scientific presentations and posters at the American Heart Association's Scientific Sessions 2011 in Orlando over the weekend.

14 Nov 2011

Hypertrophic cardiomyopathy is consistent with survival to normal life expectancy

Hypertrophic cardiomyopathy (HCM) is consistent with survival to normal life expectancy, including particularly advanced age into the tenth decade of life, with demise ultimately largely unrelated to this disease, according to a study being presented Nov. 13 at the American Heart Association (AHA) scientific sessions in Orlando, Fla.

14 Nov 2011